Stockscreener 앱 받기
1.95
8.45%
-0.18
시간 외 거래:
2.15
0.20
+10.26%
전일 마감가:
$2.13
열려 있는:
$2.12
하루 거래량:
200.83K
Relative Volume:
0.86
시가총액:
$54.11M
수익:
$210.70K
순이익/손실:
$-21.37M
주가수익비율:
-1.7727
EPS:
-1.1
순현금흐름:
$-21.10M
1주 성능:
-6.25%
1개월 성능:
-9.72%
6개월 성능:
+87.50%
1년 성능:
-58.33%
1일 변동 폭
$1.92
$2.13
1주일 범위
$1.84
$2.1452
52주 변동 폭
$0.89
$5.19
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
GANX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.95 | 54.11M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Finance
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales - MSN
GAIN THERAPEUTICS: A Microcap Stock to Love - substack.com
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Investing in Neurizon Therapeutics (ASX:NUZ) five years ago would have delivered you a 54% gain - Yahoo Finance
Does Gain Therapeutics Inc (NASDAQ: GANX) Still Need To Convince Analysts? - Stocks Register
2025 Pipeline Report: The Edge of Greatness? - Pharmaceutical Executive
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Travere Therapeutics Delivers Over 180% Gain In 6 Months - Nasdaq
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Benzinga
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
Novartis to Buy Anthos Therapeutics for $925 Million - Bloomberg
Daily Progress: Wearable Devices Ltd (WLDS) Gain 1.76, Closing at 0.95 - The Dwinnex
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research - The Globe and Mail
Janux Therapeutics Inc (NASDAQ: JANX) Gain Of 80.16% Compared To 52-Week Low; YTD Fall -26.47% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
reAlpha Tech Corp (NASDAQ: AIRE) Gain Of 70.56% Compared To 52-Week Low; YTD Fall -37.72% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Sacks Parente Golf Inc (NASDAQ: SPGC): Can The Stock Still Lose Despite An 38.15% YTD Gain? - Marketing Sentinel
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials - TipRanks
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - citybiz
Travere Therapeutics Inc (TVTX) deserves deeper analysis - US Post News
Can you now get a good deal on PTC Therapeutics Inc’s shares? - US Post News
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Philip Morris Q4: Earnings Beat, Smoke-Free Sales Gain Ground & More - Yahoo Finance
Gain Therapeutics, Inc. Provides 2025 Outlook and Progress Update on GT-02287 for Parkinson’s Disease - Nasdaq
Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching - StockTitan
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – What’s Next? - Defense World
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval - Yahoo Finance
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Gain Therapeutics To Participate in Upcoming Investor Conferences - The Manila Times
Gain Therapeutics, Inc. Announces Upcoming Presentations at BIO CEO & Investor Conference and Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
Biotech Spotlight: Gain Therapeutics Takes Center Stage at Two Major Investor Conferences - StockTitan
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Closing Figures Unveiled: Canada Goose Holdings Inc (GOOS) Gain 1.05, Closes at 10.57 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
Gene editing companies to gain from FDA’s platform designation update - BioCentury
How to interpret Omega Therapeutics Inc (OMGA)’s stock chart patterns - US Post News
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Closing Figures Unveiled: Ondas Holdings Inc (ONDS) Gain 3.55, Closes at 1.75 - The Dwinnex
2025's 10 Best-Performing Stocks - U.S News & World Report Money
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
게인 테라퓨틱스 주식 (GANX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
| Riley Jeffrey Scott | Director |
Mar 28 '24 |
Buy |
3.86 |
30,000 |
115,770 |
30,000 |
6.45%
1.23%
자본화:
|
볼륨(24시간):